Replication of the INSPIRE Trial in Healthcare Claims Data

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

98278 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-22

Study Completion Date

2021-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Replication of the IMPACT COPD Trial in Healthcare Claims Data

NCT05062304

COPD

COMPLETED

Replication of the POET-COPD Trial in Healthcare Claims Data

NCT05083429

Chronic Obstructive Pulmonary Disease

COMPLETED

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304

Pulmonary Disease, Chronic Obstructive

COMPLETED

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

NCT02173691

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tiotropium

Reference group

Tiotropium

Intervention Type DRUG

Tiotropium dispensing claim is used as the reference group.

Salmeterol/Fluticasone

Exposure group

salmeterol-fluticasone

Intervention Type DRUG

Salmeterol/Fluticasone dispensing claim is used as the exposure group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tiotropium

Tiotropium dispensing claim is used as the reference group.

Intervention Type DRUG

salmeterol-fluticasone

Salmeterol/Fluticasone dispensing claim is used as the exposure group.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 40-80 years \[0,0\] days
* Diagnosis of COPD \[all available data, 0\] days
* Clinical history of at least 1 COPD exacerbation \[all available data, -43\] days

Exclusion Criteria

* COPD exacerbation \[-42, 0\] days
* Asthma, eczema, atopic dermatitis, allergic rhinitis \[-180, 0\] days
* Known respiratory disorder other than COPD e.g. pulmonary fibrosis or interstitial lung disease (ILD), sarcoidosis, lymphangioleiomyomatosis, primary/pulmonary tuberculosis, cystic fibrosis, pulmonary hypertension/other pulmonary heart disease, lung/pulmonary malignancies, alpha-1 antitrypsin deficiency, pneumoconioses and other lung diseases due to external agents \[all available data, 0\] days
* Narrow angle glaucoma or prostatic hyperplasia or obstruction of the neck of the bladder \[-180, 0\] days
* At least one 30-day supply prescription claims for oral alfuzosin, doxazosin, tamsulosin, silodosin, finasteride 5 mg, dutasteride \[-180,0\] days
* Lung transplant or lung volume reduction surgery (LVRS) \[all available data, 0\] days
* Daily long term oxygen therapy (LTOT) \[all available data, 0\] days
* Beta-blockers (except eye drops) \[-180, 0\] days
* Evidence of alcohol, drug or solvent abuse \[-180, 0\] days
* Use of salmeterol, tiotropium and fluticasone containing inhaler use \[-180, 0\] days

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No